MedTrace Logo

Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease

NCT00852787 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2012-05-25

No results posted yet for this study

Summary

The purpose of this study is to examine the effects of the digibind drug on hemodialysis patients with high blood pressure. Digibind is used to treat toxicity from digoxin and digoxin-like molecules which may contribute to high blood pressure.

Conditions

Interventions

DRUG

Digoxin immune fab

Intravenously one time

DRUG

Placebo

Intravenously one time

Sponsors & Collaborators

  • University of Toledo Health Science Campus

    collaborator OTHER

  • National Institute on Aging (NIA)

    lead NIH

Principal Investigators

  • Deepak Malhotra, MD, PhD · University of Toledo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00852787 on ClinicalTrials.gov